NSCLC
Conditions
Interventions
1:Group rHuTPO: Patients were treated with recombinant human thrombopoietin(rHuTPO)on d2,d4,d6,d9 of chemotherapy cycle.
2:Patients were treated with recombinant human interleukin-11(rHuIL-11)on d9-d15 after chemotherapy
Sponsors
Shanghai Chest Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Over 18 years old, Male or females; Patients with NSCLC for whom treatment with gemcitabine and cisplatin or carboplatin; Platele counts is less than or equal to 50*10^9/L during Screening chemo cycle ECOG PS score is less than or equal to 2; The predicted life expectancy is greater than or equal to 3 months Written informed consent
Exclusion criteria
Exclusion criteria: Pregnant or nursing women; Known history of severe anaphylactic reaction to biologics Uncontrolled severe infection History of bone or central nervous system metastasis History of platelet disorder; Active bleeding
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The time to achieve platelet count >=75*10^9/L and >=100*10^9/L after rHuTPO or rHuIL-11.;The number of platelet transfusions after rHuTPO or rHuIL-11.;The platelet count on 21th day after rHuTPO or rHuIL-11.;The mean minimal and maximal platelet count after rHuTPO or rHuIL-11.;The duration of platelet count <50*10^9/L after rHuTPO or rHuIL-11.; | — |
Countries
China
Contacts
Public ContactShun Lu
Outcome results
None listed